ArticleJournal of thoracic disease2024
Rethinking how mobile units can catalyze progress on lung cancer screening: a scoping review of what we have learned.
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and implementation challenges of mobile low-dose computed tomography units for early lung cancer detection: a systematic review.Frontiers in public health · 2026Pooled it
- Bronchus and lung cancer-related mortality trends in the United States from 1999 to 2023.Journal of cardiothoracic surgery · 2026Article
- Patient and Healthcare Provider Barriers in the LDCT Lung Cancer Screening Continuum.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Toward equitable regenerative medicine: a health equity research framework for emerging regenerative treatments.Regenerative medicine · 2025Review
- Teleconsultation for Delivering Low-Dose Computed Tomography Reports in a Mobile Lung Cancer Screening Program in a Low- and Middle-Income Country: A Cross-Sectional Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: Despite United States Preventive Services Task Force (USPSTF) recommendations, low uptake of lung cancer screening (LCS) highlights the need for measures to promote adoption. This scoping review aims to outline the global landscape of mobile low-dose computed tomography (LDCT) platforms, summarizing research and evaluating efficacy in screening at-risk populations. Methods: We comprehensively searched Cumulative Index to Nursing and Allied Health Literature (CINAHL), PubMed, Embase, Scopus, and Web of Science for articles published between 2017 and 2023. Selected studies focused on mobile LCS programs using LDCT, providing details on program location, design, sample size, age, targeted population, lung cancer detection rate, and outcomes. Only studies meeting these criteria were considered. Results: The search found 12 studies meeting inclusion criteria, documenting ten mobile LDCT platforms across several countries. These studies primarily evaluated platform effectiveness in screening populations at risk, particularly targeting individuals who have ever smoked, high-risk individuals, and underserved populations. Two studies compared outcomes between mobile and hospital-based screening, while 10 other studies reported outcomes from mobile LDCT platforms. In US studies, most participants in mobile LCS programs came from rural areas, were uninsured or under-insured, and included a notable number of racial/ethnic minorities. The frequency of lung cancer diagnoses ranged from 0.33% to 3%, with the majority (80%) of detected at stages I and II. Conclusions: The mobile LDCT platforms emerge as a powerful solution to enhance access to LCS, especially for marginalized populations. By improving screening rates and enabling early detection, these platforms hold promise in narrowing healthcare disparities. Mobile LDCT presents a crucial opportunity to save lives and promote equity in healthcare access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.